PhotoCure ASA (OSL:PHO)
kr 49.3 0.4 (0.82%) Market Cap: 1.34 Bil Enterprise Value: 1.05 Bil PE Ratio: 94.81 PB Ratio: 2.67 GF Score: 78/100

Q4 2020 Photocure ASA Earnings Call Transcript

Mar 03, 2021 / 01:00PM GMT
Release Date Price: kr130 (+13.04%)
Daniel Schneider
Photocure ASA - President & CEO

All right. Well, good afternoon and good morning, depending on where you're calling in from around the world. This is Photocure's results for year-end and fourth quarter 2020. I'm Dan Schneider, President and CEO. And with me today is Erik Dahl, CFO.

Usual disclaimers are in place for today's presentation. So let's go with a little bit of the background on Photocure and the product Hexvix/Cysview. We treated over 0.5 million bladder cancer patients worldwide. In fact, I think the number has reached 637,000 and growing rapidly. We have direct sales in both the U.S. and Europe. And otherwise, worldwide partnerships around the globe, recently announcing our China partnership with Asieris.

We do about NOK 256.5 million in 2020. We're approved for use in over 30 countries. We currently have 90 employees, as we've recently built our European operations up. And as I said, we treated well over 0.5 million patients.

Our strategy is pretty straightforward. Strategy steps 1 and 2 are focused on Hexvix/Cysview, ways to accelerate the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot